Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  afuresertib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-6 of 6 for your search:
Start Over
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: PKB112835, NCT00881946
Dose-finding Study in Platinum-Resistant Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: PKB116611, 2012-002483-27, NCT01653912
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 115125, NCT01428492
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 115829, NCT01476137
Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers
Phase: Phase I
Type: Biomarker/Laboratory analysis
Status: Completed
Age: 18 to 40
Sponsor: Pharmaceutical / Industry
Protocol IDs: 117313, NCT01827644
Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib
Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Completed
Age: 18 to 40
Sponsor: Pharmaceutical / Industry
Protocol IDs: 201039, NCT02040480
Start Over